 Shares of early-stage prostate cancer concern ESSA Pharma Inc. are down 90 since May 2021 as trial data delays and vague messaging suggest that its therapy is running into issues about effectiveness and the market size for its therapy. It does not help that management has not conducted a conference call to better explain the clinical trial situation. 